Disclosed is the use of a tramadol material and a phosphodiesterase (PDE) inhibitor in the manufacture of a composition for treating comorbid premature ejaculation and erectile dysfunction, wherein the PDE inhibitor is a PDE5 inhibitor, or a combination of two or more of the foregoing PDE5 inhibitors.